Eisai: Retraining the Sales Force After an Acquisition

In the Eisai Zonegran settlement, Eisai agreed to pay $11 million to resolve civil allegations that its off-label promotion caused government health care programs to pay for uses they did not cover. Eisai had bought the epilepsy drug and its sales force, then retrained the people selling it. The government’s account acknowledged those efforts and still alleged that some off-label marketing continued.

The Department of Justice announced the settlement on December 15, 2010. Its $214.5 million headline covered separate resolutions with Elan and Eisai. Eisai’s agreement addressed its own alleged promotion and the government claims that followed the purchase.

This pharmaceutical fraud case turns on what happened to a working sales operation. The drug changed hands. The people carrying its message came with it.

What Was Zonegran Approved For?

According to the Justice Department’s account of the case, the Food and Drug Administration had approved Zonegran to treat partial epileptic seizures in adults over sixteen. It had not approved the other uses described in the settlement announcement.

The government described Elan’s promotion for mood stabilization in mania and bipolar disorder, migraine and chronic daily headaches, eating disorders, obesity or weight loss, and seizures in children under sixteen. Those uses broadened both the conditions the drug was sold to treat and the patients it was sold for.

Selling an epilepsy drug to treat a different condition expands the intended market. Promoting it for children crosses a different part of the approval boundary, even when the condition is still seizures.

What Is Considered Off-Label Promotion?

Off-label promotion means marketing a drug for a use outside its FDA-approved labeling. In the Zonegran account, the government described a campaign aimed at non-epilepsy prescribers, reaching beyond the drug’s approved adult seizure use.

The government also alleged that Elan paid kickbacks to physicians to encourage those prescriptions. Its civil case connected the promotion to claims for uses that were not medically accepted indications and therefore were not covered by government programs.

That was the commercial history behind Eisai’s purchase. In that account, the earlier campaign had already put a broader set of uses in front of prescribers. The acquisition brought the people selling the drug into the buyer’s business, along with the task of changing what they said about it.

Eisai Bought the Drug and the Sales Force

Eisai purchased Zonegran and its sales force from Elan in April 2004. The Justice Department described what followed:

The retraining addressed the sales message. The next question is what reached prescribers afterward. A training session and a sales call can tell different stories.

For a sales or compliance employee, that puts the practical question in familiar terms. What changed in the instructions, and what changed in the field? We look at that difference with the person who knows the business, including how the company’s response affected the prescriptions it pursued.

What the Eisai Settlement Paid For

The Eisai settlement resolved allegations under the False Claims Act and related state laws that the company promoted Zonegran and caused false claims for noncovered uses. The agreement divided the payment between the federal government and state Medicaid programs.

The payment allegation gives the sales story its consequence. According to the government, the promoted uses were not medically accepted indications, yet claims for them reached publicly funded healthcare programs. The alleged cost fell on taxpayers through prescriptions the programs did not cover.

The term medically accepted indication matters because it connects the patient’s use to payment. Medicaid’s definition includes uses the agency approved and uses supported by citations in specified drug reference works, called compendia.

That is why we examine the promoted use and the reimbursement support together. The sales message explains which prescriptions the company wanted. The coverage information explains how those prescriptions reached public payment. Eisai’s settlement joined those questions in the government’s allegation that its promotion caused false claims.

Why the Patient’s Use Matters

The drug’s name alone does not tell the payer which condition it treated. A 2018 Managed Care article, Indication-Specific Drug Pricing–Simple in Theory, Complex in Reality, described a practical information gap: the indication may be in the electronic medical record without being captured when the pharmacy dispenses the drug.

In a promotion case, that gap can matter. A dispensing record and a clinical record may hold different parts of the same prescription’s story. A representative may know which use the campaign pursued; a clinician may know why the patient received the drug. Connecting that knowledge to the claim is how the commercial account becomes a payment account.

What Sales and Medical Affairs Employees May Know

An insider may know how the company translated a promoted use into sales instructions, study presentations and incentives. In a business that has just changed owners, the instructions before and after retraining are a natural place for us to compare the stated correction with the work employees were expected to do.

A separate whistleblower complaint against ISTA Pharmaceuticals shows how directly a sales instruction can connect an off-label use to compensation. The whistleblower alleged that ISTA divided off-label Xibrom uses into sales categories it called buckets. The complaint reproduced this company instruction:

The same complaint alleged that representatives received training on answering challenges to a study that lacked statistical significance. It also described sales budgets used to print preoperative instruction sheets intended to encourage off-label prescriptions. The alleged campaign reached the response to a physician’s objection, the paperwork used with patients and the representative’s bonus.

That parallel shows why the details of a sales job matter. The words in a presentation, the answer a representative is trained to give and the activity a bonus rewards can reveal the commercial purpose. An employee who knows those details can explain what a general instruction to stop off-label marketing actually changed.

What Is an Example of a Pharmaceutical Whistleblower Case?

The Eisai Zonegran settlement resolved allegations in a qui tam case brought by a Massachusetts physician. The same whistleblower’s case also underlay Elan’s civil resolution. The Justice Department announced that the physician would receive more than $1 million from the federal share of Eisai’s civil recovery.

The case began with someone on the prescribing side of the business. That perspective complements what an employee knows about the internal campaign: the physician receives the message the sales force is trained to deliver.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Changed After the Training

If you worked in sales, medical affairs or compliance and saw a promotional campaign continue after retraining, speak to one of our whistleblower experts about what the sales force was still expected to sell. We build your strongest pharmaceutical whistleblower case around the internal decisions and the government payments they reached, bringing in pharmaceutical fraud whistleblower lawyers who understand promotion and reimbursement. We remain your partners as that account becomes a case and through the pursuit of a recovery.